Docket No. 02N-0101. U.S. Food and Drug Administration, 9. April 2002, abgerufen am 30. Januar 2014 (englisch): „In 1999, amineptine products were voluntarily removed from the market in France and Portugal due to risks of misuse and addiction.“
Docket No. 03N-0015. U.S. Food and Drug Administration, 3. Februar 2003, abgerufen am 30. Januar 2014 (englisch): „It has been withdrawn from the market in France, where the drug was developed a few decades ago, for reasons of considerable hepatotoxicity and abuse.“
